K2M Grows Biologics Offering with Expansion of VESUVIUS Product Family
K2M, Inc., the largest privately held spinal device company in the world focused on developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced another expansion of the company’s U.S. biologics offering with the addition of a new product line to the VESUVIUS™ Osteobiologic Systems.
VESUVIUS DBM Putty will join the rapidly growing portfolio already featuring VESUVIUS Demineralized Fibers and VESUVIUS Demineralized Sponge. Processed by LifeNet Health®, a leading allograft bio-implant and regenerative medicine company, these products are treated with a patented ALLOWASH XG® sterilization process and PAD® demineralization technology to protect Bone Morphogenic Proteins (BMPs), while ensuring optimal osteoinductive potential. VESUVIUS DBM Putty incorporates proprietary bone-fiber technology and a glycerol carrier to provide an enlarged surface area to facilitate attachment, migration, and distribution of cells within the graft material.
According to Paul Savas, MD, K2M’s Medical Director for Tissue Products and orthopedic surgeon in Williamsburg, Virginia, “K2M’s launch of VESUVIUS DBM Putty is an important expansion of their biologics portfolio. DBM Putty is a commonly used osteobiologics solution for spinal fusions, and this offering incorporates a unique carrier for handling characteristics, while incorporating LifeNet’s PAD process to achieve the ideal residual calcium necessary for optimal osteoinductive potential. Products can be designated as demineralized if the residual calcium level is < 8%. However, studies show that residual calcium in the range of 1 to 4% provides the most osteoinductive potential. This is the range that the PAD process targets consistently.”
“The launch of this new addition to the VESUVIUS product family demonstrates K2M’s continued focus on growing our presence in the biologics market,” stated Eric Major, K2M’s President and CEO. “VESUVIUS DBM Putty complements and enhances K2M’s comprehensive and innovative spine portfolio.”
K2M, Inc. is the largest privately held spinal device company in the world focused on the research, development, and commercialization of innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures. The company is recognized as a global leader in providing unique technologies for the treatment of deformity, degenerative, trauma, and tumor spinal patients. K2M’s product development pipeline includes: spinal stabilization systems, minimally invasive systems, biologics, and other advancing technologies, such as motion preservation, annular repair, and nucleus replacement. Additional information is available online at www.K2M.com.